Table 1. Information of patients and healthy control.

MS+IFN β1a: MS patients were treated with interferon β- a 30 mcg IM weekly for at least 12 months. MS+Natalizumab: MS patients received at least three courses of natalizumab infusion (300mg IV), following the recommendations outlined in the US Food and Drug Administration-mandated Tysabri Outreach Unified Commitment to Health (TOUCH) program, and tested negative for anti-natalizumab antibodies. All patients gave written informed consent, and all study protocols were approved by CCF IRB.